Evaluation of Artemisone Combinations in Aotus Monkeys Infected with *Plasmodium falciparum*}

Nicanor Obaldia III, 1 Barbara M. Kotecka, 2 Michael D. Edstein, 2 Richard K. Haynes, 3 Burkhard Fugmann, 4 Dennis E. Kyle, 2 and Karl H. Rieckmann 2*

Tropical Medicine Research, Malaria Drug and Vaccine Evaluation Center/Gorgas Memorial Institute of Health Studies, Panama, Panama; 1 Australian Army Malaria Institute, Brisbane, Australia; 2 Department of Chemistry, Open Laboratory of Chemical Biology, Institute of Molecular Technology for Drug Discovery and Synthesis, Hong Kong University of Science and Technology, Kowloon, Hong Kong; and Bayer Innovation, Dusseldorf, Germany

Received 9 April 2009/Returned for modification 11 May 2009/Accepted 1 June 2009

Artemisone (single oral dose, 10 mg/kg of body weight) cured nonimmune Aotus monkeys of their *Plasmodium falciparum* infections when combined with mefloquine (single oral dose, 5 and 10 mg/kg but not 2.5 mg/kg). In combination with amodiaquine (20 mg/kg/day), artemisone (10 mg/kg/day) given orally for 3 days cured all infected monkeys. Three days of treatment with artemisone (30 mg/kg/day) and clindamycin (100 mg/kg/day) was also curative.

Increasing parasite resistance to standard antimalarial drugs is encouraging more-widespread use of artemisinin and some of its derivatives—artesunate, artemether, and dihydroartemisinin—for the treatment of malaria. Although they act more rapidly than other antimalarials, 3-day monotherapy courses are associated with a high parasite recrudescence rate, presumably due to the short pharmacological half-lives of the artemisinins. Patient compliance with longer, curative treatment courses is poor, especially in malarious areas with limited health infrastructures. Shorter 3-day courses are curative only when combined with other less-effective but longer-acting drugs. Artemisinin-based combination therapy, administered for 3 days, has now become the latest tool for curing multidrug-resistant malaria infections and retarding the development of drug resistance (1, 18).

Artemisone (BAY 44-9585) (ASO), a 10-alkylaminoartemisinin, is a new artemisinin derivative that is being developed according to international drug regulatory standards (6). In contrast to some artemisinins (2, 22), ASO displays low lipophilicity and negligible neuro- and cytotoxicity in vitro and in vivo assays (6, 12). Compared to artesunate, the most widely used artemisinin derivative, ASO shows greater activity (6, 16, 21) in the Peters 4-day test rodent-*Plasmodium berghei* model (15) and against multidrug-resistant isolates of *Plasmodium falciparum* both in vitro (4) and in the ex vivo bioassay Saimiri/Aotus monkey model (8). Preliminary studies at the Army Malaria Institute (AMI) Australia also showed that malaria-infected *Aotus* monkeys clear parasites faster after a 3-day course of ASO (total dosage, 30 mg/kg of body weight) than after the same course of artesunate and, although only one of four monkeys was cured, parasite recurrences tended to occur later in the ASO-treated monkeys (6).

These encouraging results prompted AMI to determine whether the addition of mefloquine (MQ) to ASO might cure infected monkeys. Since many patients are not cured of their malaria infections because they fail to complete their treatment course, studies were initiated with short 1-day courses of treatment. After approval by the AMI Animal Ethics Committee (approval no. 03/2000), naive *Aotus* monkeys, weighing between 0.68 and 1.29 kg, were inoculated intravenously with 1 × 10⁶ to 6 × 10⁷ parasites of the FVO strain of *P. falciparum*, which is resistant to chloroquine and quinine but susceptible to pyrimethamine and MQ. Three to four days after the onset of patency, parasite counts had reached between 29.2 × 10⁸ and 325.0 (median, 60.0) × 10³/µl blood. Monkeys then received various 1-day regimens of ASO alone or ASO in combination with MQ by being allowed to swallow drugs suspended in orange juice by slow expulsion from a syringe. After treatment, thick blood smears were examined daily by counting parasites against 500 leukocytes. When no parasites were detected in 200 microscopic fields, follow-up blood smears were examined twice a week for at least 60 days after treatment. Body weights, hematocrit values, and leukocyte and platelet counts were monitored carefully after treatment, and any monkeys not responding appropriately to treatment were cured of their infections with MQ (20 mg/kg). The results from AMI are summarized in Table 1.

One-day treatment of two monkeys with ASO (10 mg/kg) every 2 h on two or three occasions (total dosage, 20 or 30 mg/kg) produced a 300- to 2,000-fold reduction in parasite counts but did not clear parasitemia, indicating that multiple doses on 1 day are not as effective as the same total dosage administered over 3 days (6). When a single dose of MQ (2.5, 5.0, or 12.5 mg/kg) was added to ASO (10 mg/kg), all four monkeys cleared parasitemia by day one. Except for the monkey receiving the lowest MQ dosage, all monkeys were cured. It is noteworthy that the dosage of 5 mg/kg is equivalent to 100 mg MQ administered to a 60-kg human adult, using a 3:1 ratio to convert the body surface area from monkey to human (5).

Since this is far below the curative MQ dose, this drug combination may prove useful in areas with low malaria transmis-
sion, with or without MQ resistance (3, 13, 23). It is likely to be less useful in areas with high levels of malaria transmission (e.g., Africa) because MQ’s very long persistence in the body (20) would favor the rapid development of MQ resistance in reinfected patients.

With this in mind, studies were approved by Gorgas Memorial Institutional Animal Care and Use Committee (approval no. 2000/02) to assess two less-persistent, potent partner drugs, amodiaquine (AQ) and clindamycin (CM), at the Tropical Medicine Research, Malaria Drug and Vaccine Evaluation Center/Gorgas Memorial Institute of Health Studies (TMR/ICGES) Panama, using a larger group of monkeys than was available at AMI. Although AQ is a 4-aminoquinoline drug, parasites are often less resistant to it than to chloroquine (14, 19, 24). It is less expensive than most other antimalarial drugs and is now being used increasingly in Africa in combination with either artesunate (7, 11) or sulfadoxine-pyrimethamine (11, 25). Although CM is more expensive, parasite resistance to this short-acting antibiotic is unknown, and in combination with artesunate, quinine, or chloroquine, it can be used safely to treat children and pregnant women (9, 10, 17). Experimental conditions at TMR/ICGES were essentially similar to those at AMI, but drugs were administered by gastric intubation and treatment was usually started at lower parasite counts, ranging from 4.5 × 10⁸ to 71.1 (median = 21.6) × 10⁸/µL blood. The results from TMR/ICGES are summarized in Table 2.

One-day treatment with a single noncurative dose of ASO (30 mg/kg) plus AQ (20 mg/kg) cleared parasitemia but failed to cure any of the three monkeys. Two-day treatment with ASO (30 mg/kg/day) plus AQ (30 mg/kg/day) cured two of the three monkeys. Three-day treatment combining ASO (10 mg/kg/day) with AQ (20 mg/kg/day) cured all three monkeys receiving this drug regimen; however, both drugs given alone for 3 days failed to cure six of six monkeys. Further studies with ASO (30 mg/kg/day) and CM (100 mg/kg/day) showed that 3 days of treatment with this drug combination cured three of three monkeys whereas one of two monkeys was not cured using ASO (30 mg/kg/day) alone.

Our results show that administering ASO plus AQ for 3 days was curative at an AQ dosage comparable to that employed for treating malaria patients (using a 3:1 conversion factor) and at a daily ASO dosage that was one-third of that used in the 1- or 2-day treatment course. Considering these results in conjunction with previous findings at AMI (6), it is clear that various total dosages (20 to 90 mg/kg) of ASO alone, administered over 1 to 3 days, are unable to cure nonimmune monkeys. However, monkeys can be cured when ASO is combined with a single, subcutractive dose of MQ or with a 3-day treatment course of either AQ or CM.

The results of our studies, using the Aotus-P. falciparum model, indicate the need for investigations with humans to determine optimum drug regimens for treating falciparum infections. A phase I clinical trial has shown ASO to be well tolerated and safe in healthy subjects (12). With the possible exception of MQ, it is likely that ASO combinations will have to be given for 3 days if a cure is to be achieved in most patients having little or no immunity to falciparum malaria. In view of ASO’s efficacy and low toxicity (6), ASO combination therapy could become a very important addition to our sparse armamentarium against drug-resistant malaria.

We thank William Otero, Jorge Aparicio, Camilo Marin, Maritza Brewer, and Gladysz Calviño for their technical and administrative support of the study at TMR/ICGES. We also appreciate the support provided by Anthony Kotecki and Kerryn Rowcliffe during the Aotus studies at AMI.

The development and assessment of ASO received financial support from the Government of the Hong Kong SAR University Grants Committee Areas of Excellence Fund, Medicines for Malaria Venture, and Bayer AG.

The opinions expressed are those of the authors and do not necessarily reflect those of the Joint Health Command or any extant Australian Defense Force health policy.

REFERENCES


